financetom
Business
financetom
/
Business
/
Braskem Q4 Net Loss Shrinks, Revenue Drops -- Shares Surge
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Braskem Q4 Net Loss Shrinks, Revenue Drops -- Shares Surge
Mar 20, 2024 9:14 AM

11:57 AM EDT, 03/20/2024 (MT Newswires) -- Braskem ( BAK ) reported Q4 net loss Tuesday of 1.58 billion Brazilian reals ($317 million), narrowing from a loss of 1.71 billion Brazilian reals a year earlier.

Analysts polled by Capital IQ expected a loss of 641 million Brazilian reals.

Revenue for the quarter ended Dec. 31 was 16.69 billion Brazilian reals, down from 18.99 billion Brazilian reals a year earlier.

Analysts surveyed by Capital IQ expected 17.04 billion Brazilian reals.

The company shares were up over 11% in recent trading on Wednesday.

Price: 10.02, Change: +1.03, Percent Change: +11.40

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kohl's Fiscal Q2 Adjusted Earnings, Net Sales Fall; 2025 Outlook Revised
Kohl's Fiscal Q2 Adjusted Earnings, Net Sales Fall; 2025 Outlook Revised
Aug 27, 2025
07:29 AM EDT, 08/27/2025 (MT Newswires) -- Kohl's (KSS) reported fiscal Q2 adjusted earnings Wednesday of $0.56 per diluted share, down from $0.59 a year earlier. Analysts polled by FactSet expected $0.30. Net sales for the quarter ended Aug. 2 were $3.35 billion, compared with $3.53 billion a year earlier. Analysts surveyed by FactSet expected $3.32 billion. For fiscal 2025,...
Merck's Phase 3 Trial for Metastatic Breast Cancer Treatment Doses First Patient
Merck's Phase 3 Trial for Metastatic Breast Cancer Treatment Doses First Patient
Aug 27, 2025
07:28 AM EDT, 08/27/2025 (MT Newswires) -- Merck ( MRK ) said Wednesday its phase 3 trial for investigational patritumab deruxtecan targeting metastatic breast cancer has dosed its first patient. The trial evaluates the efficacy and safety of investigational patritumab deruxtecan versus investigator's choice of treatment in patients with unresectable locally advanced or metastatic hormone receptor positive, HER2 negative breast...
ECARX's Antora 1000 Pro Receives ASPICE v4.0 CL3 Certification
ECARX's Antora 1000 Pro Receives ASPICE v4.0 CL3 Certification
Aug 27, 2025
07:29 AM EDT, 08/27/2025 (MT Newswires) -- ECARX ( ECX ) said Wednesday its Antora 1000 Pro computing platform has received Automotive SPICE v4.0 Capability Level 3 (CL3) certification. The platform previously obtained the ASPICE v3.1 CL2 certification in September 2020, CMMI CL3 accreditation in May 2022, and ASPICE v3.1 CL3 certification in August 2022. ...
J.M. Smucker Fiscal Q1 Adjusted Earnings, Sales Fall; Full-Year Revenue Outlook Updated
J.M. Smucker Fiscal Q1 Adjusted Earnings, Sales Fall; Full-Year Revenue Outlook Updated
Aug 27, 2025
07:29 AM EDT, 08/27/2025 (MT Newswires) -- J.M. Smucker (SJM) reported fiscal Q1 adjusted earnings Wednesday of $1.90 per diluted share, down from $2.44 a year earlier. Analysts polled by FactSet expected $1.93. Net sales for the quarter ended July 31 were $2.11 billion, compared with $2.13 billion a year earlier. Analysts surveyed by FactSet expected $2.12 billion. For fiscal...
Copyright 2023-2026 - www.financetom.com All Rights Reserved